NIH awards $50.7M to Microgem for biotech R&D, citing unique capabilities

Contract Overview

Contract Amount: $50,734,479 ($50.7M)

Contractor: Microgem US Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2020-08-28

End Date: 2022-08-27

Contract Duration: 729 days

Daily Burn Rate: $69.6K/day

Competition Type: NOT AVAILABLE FOR COMPETITION

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: RAPID ACCELERATION OF DIAGNOSTICS ( RADX) PROGRAM: TECH PROJECT #2322 MICROGEM (MICROLAB)

Place of Performance

Location: CHARLOTTESVILLE, CHARLOTTESVILLE CITY County, VIRGINIA, 22903

State: Virginia Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $50.7 million to MICROGEM US INC for work described as: RAPID ACCELERATION OF DIAGNOSTICS ( RADX) PROGRAM: TECH PROJECT #2322 MICROGEM (MICROLAB) Key points: 1. Contract awarded on a sole-source basis, limiting competitive price discovery. 2. Significant investment in research and development within the biotechnology sector. 3. Contract duration of 729 days suggests a focused, project-based initiative. 4. Firm-fixed-price structure aims to control costs, but requires careful scope management. 5. Awarded to Microgem US Inc., indicating a reliance on specialized expertise. 6. Potential for innovation in diagnostics, aligning with public health goals.

Value Assessment

Rating: fair

The contract value of $50.7 million for a 729-day research and development project appears substantial. Benchmarking this against similar sole-source contracts for specialized biotechnology R&D is challenging due to the unique nature of such awards. The firm-fixed-price structure suggests an attempt to cap costs, but the absence of competitive bidding makes it difficult to definitively assess value for money. Without more comparable data, it's hard to determine if the pricing is optimal.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. The justification for this approach likely stems from the perceived unique capabilities or proprietary technology of Microgem US Inc. The absence of competition means there were no other bidders to drive down prices through a bidding process, potentially leading to a higher cost for the government compared to a competed contract.

Taxpayer Impact: Sole-source awards limit opportunities for taxpayers to benefit from competitive pricing, as the government does not leverage multiple bids to secure the best possible value.

Public Impact

The primary beneficiary is Microgem US Inc., which receives significant funding for its research. The services delivered are focused on research and development in biotechnology, specifically diagnostics. The geographic impact is primarily tied to Microgem's operational location, likely in Virginia. Workforce implications include potential job creation or utilization of specialized scientific talent within Microgem.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price competition, potentially increasing costs for taxpayers.
Lack of transparency in the sole-source justification could obscure potential alternatives.
Performance risks are inherent in R&D projects, with outcomes not guaranteed.
Dependence on a single contractor for specialized R&D may pose supply chain risks.

Positive Signals

Focus on critical R&D in diagnostics addresses important public health needs.
Firm-fixed-price contract provides cost certainty if scope is well-defined.
Award to a specific company suggests alignment with a strategic research objective.
NIH's involvement indicates a level of scientific and programmatic oversight.

Sector Analysis

This contract falls within the Biotechnology Research and Development sector, a rapidly evolving field focused on leveraging biological processes for innovation. The market is characterized by high R&D intensity, specialized expertise, and significant government investment. Comparable spending benchmarks are difficult to establish for sole-source awards of this nature, as they are driven by specific technological needs rather than broad market competition. The National Institutes of Health (NIH) is a major funder of such research.

Small Business Impact

This contract does not appear to involve a small business set-aside, as Microgem US Inc. is the prime contractor. There is no information provided regarding subcontracting plans or implications for the small business ecosystem. As a sole-source award, it is unlikely to create opportunities for small businesses through subcontracting unless explicitly mandated by the prime contractor.

Oversight & Accountability

Oversight for this contract would primarily reside with the National Institutes of Health (NIH), a division of the Department of Health and Human Services. As a definitive contract, it is subject to standard federal procurement regulations and oversight mechanisms. Transparency regarding the sole-source justification and performance metrics would be key accountability measures. The specific Inspector General for HHS would have jurisdiction over potential fraud, waste, or abuse.

Related Government Programs

National Institutes of Health (NIH) Research Grants
Biotechnology Research and Development Programs
Department of Health and Human Services (HHS) Contracts
Advanced Diagnostics Initiatives

Risk Flags

Sole-source award limits competition.
R&D contracts carry inherent performance risks.
Lack of detailed performance metrics in summary data.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $50.7 million to MICROGEM US INC. RAPID ACCELERATION OF DIAGNOSTICS ( RADX) PROGRAM: TECH PROJECT #2322 MICROGEM (MICROLAB)

Who is the contractor on this award?

The obligated recipient is MICROGEM US INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $50.7 million.

What is the period of performance?

Start: 2020-08-28. End: 2022-08-27.

What is the specific technological innovation or capability that justified the sole-source award to Microgem US Inc. for the RADx program?

The provided data does not detail the specific technological innovation or unique capability that justified the sole-source award to Microgem US Inc. for the RAPID ACCELERATION OF DIAGNOSTICS (RADx) program. Sole-source justifications typically require extensive documentation outlining why only one contractor can meet the government's needs, often due to proprietary technology, unique expertise, or critical urgency where competition is not feasible. For this contract, the specific rationale would likely be found in the contract award justification documentation (e.g., a Justification for Other Than Full and Open Competition - JOFOC) filed with the contract. This document would elaborate on Microgem's specific contributions or intellectual property that made them the only viable option for this particular research and development effort within the RADx initiative.

How does the $50.7 million contract value compare to other R&D contracts awarded by NIH in the biotechnology sector?

Comparing the $50.7 million contract value to other R&D contracts awarded by NIH in the biotechnology sector requires access to a broader dataset of NIH procurements. However, $50.7 million is a substantial sum, indicating a significant investment in a specific research project. NIH funds a wide range of R&D activities, from small grants to large-scale program contracts. Contracts of this magnitude are typically awarded for major research initiatives, platform development, or multi-year projects requiring substantial resources and specialized expertise. Without specific comparable contract data, it's difficult to definitively state whether this award is high or low relative to the average for similar biotechnology R&D efforts, but it signifies a major commitment by NIH.

What are the key performance indicators (KPIs) or milestones associated with this contract, and how will Microgem's performance be measured?

The provided data does not specify the key performance indicators (KPIs) or milestones for this contract. For a research and development contract, especially one with a firm-fixed-price structure, performance measurement typically revolves around the achievement of defined research objectives, delivery of specific prototypes or data, adherence to project timelines, and potentially the successful validation of diagnostic technologies. The contract documents themselves would contain the detailed statement of work (SOW) and any associated performance standards or milestones. NIH contracting officers and technical monitors would be responsible for overseeing Microgem's progress against these agreed-upon metrics throughout the contract's duration.

What is Microgem US Inc.'s track record with federal contracts, particularly with NIH or other health-related agencies?

The provided data indicates that Microgem US Inc. is the contractor for this specific award. To assess their track record with federal contracts, particularly with NIH or other health-related agencies, one would need to consult federal procurement databases like SAM.gov or FPDS. These databases would reveal the history of contracts awarded to Microgem, including the agencies involved, contract values, types of services rendered, and performance history (if available). A review of this history would indicate their experience level, success rate, and any potential red flags or positive performance indicators relevant to their ability to execute this current R&D contract.

Given the sole-source nature, what steps were taken to ensure fair and reasonable pricing for this $50.7 million award?

For sole-source awards, ensuring fair and reasonable pricing typically involves a thorough price analysis conducted by the contracting officer. This analysis might include reviewing the contractor's cost proposals, historical pricing data for similar work (if available), commercial pricing, or using independent government cost estimates. In cases where direct comparisons are difficult, agencies may rely on negotiation techniques and expert consultation. The specific steps taken to ensure fair and reasonable pricing for this $50.7 million award would be documented in the contract file, likely including a price negotiation memorandum (PNM) that details the analysis performed and the basis for concluding that the price was acceptable.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: MEDICAL SERVICES › LABORATORY TESTING SERVICES

Competition & Pricing

Extent Competed: NOT AVAILABLE FOR COMPETITION

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 705 DALE AVE STE D, CHARLOTTESVILLE, VA, 22903

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Self-Certified Small Disadvantaged Business, Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $50,734,479

Exercised Options: $50,734,479

Current Obligation: $50,734,479

Actual Outlays: $50,734,479

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Timeline